Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MTR | Q99707 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22291961 | 0.88 | CRBN (0.53) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL30827429 | 0.85 | CRBN (0.54) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL26891453 | 0.85 | CRBN (0.54) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL20128652 | 0.83 | CRBN (0.52) | CRBNHDAC6MTRKMT2AADORA2A | |
| SCHEMBL27347098 | 0.83 | CRBN (0.52) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL22291919 | 0.79 | CRBN (0.53) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL24922084 | 0.78 | CRBN (0.45) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL30121132 | 0.78 | CRBN (0.63) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL824532 | 0.78 | CRBN (0.63) | CRBNHDAC1HDAC6MTRKMT2A | |
| SCHEMBL17169682 | 0.78 | CRBN (0.58) | CRBNHDAC1HDAC6MTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-18 | — | — | US | disclosed |
| US-10836721-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200325102-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-10-15 | — | — | US | disclosed |
| US-10730835-B2 | Thalidomide analogs and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, HEALTH AND HUMAN SERVICES (US) | 2020-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836721-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CRBN 233/4885HDAC1 383/4885HDAC6 1039/4885 |
| US-10730835-B2 | Thalidomide analogs and methods of use | PGF, TYMP, TPMT | CRBN 233/4885HDAC1 383/4885HDAC6 1039/4885 |
| US-20210047267-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | CRBN 233/4885HDAC1 383/4885HDAC6 1039/4885 |
| US-20200325102-A1 | THALIDOMIDE ANALOGS AND METHODS OF USE | PGF, TYMP, TPMT | CRBN 233/4885HDAC1 383/4885HDAC6 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.